Theratechnologies Launches Phase 2 Clinical Trial to Investigate Tesamorelin for the Treatment of COPD-Associated Muscle Wasting - MarketWatch

MONTREAL, QUEBEC, Sep 06, 2011 (MARKETWIRE via COMTEX) -- Theratechnologies Inc. CA:TH 2.07% THER -2.24% announced today that it has initiated the patient screening process of its phase 2 clinical trial investigating tesamorelin for the treatment of muscle wasting in patients suffering from chronic obstructive pulmonary disease (COPD). This follows the investigator meeting, which took place in Montreal, Quebec, Canada, on August 27, 2011. The objective of the study is to evaluate the effects of two doses of a new formulation of tesamorelin on lean body mass (LBM), patient functionality and quality of life.

Theratechnologies Launches Phase 2 Clinical Trial to Investigate Tesamorelin for the Treatment of COPD-Associated Muscle Wasting - MarketWatch